Takeda Pharmaceutical Co Ltd (TAK)
Takeda makes and sells branded prescription medicines, selling to hospitals, insurers and government health programs in Japan, the U.S. and Europe. It last closed at $21.77 on Nov 20, up 1.68% on the day. Over the last 12 months TAK insiders bought $0 of stock on the open market and sold $15.2M, according to SEC Form 4 filings.
Key Stats
Fiscal 2025Not reported for this period.
From TAK's SEC filings, latest 20-F for the period ending Mar 31, 2025 (filed Jun 17). Figures are in JPY. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Technical AnalysisPrices may be delayed
The stock is 4% above its 20 day and 9% above its 50 day average. It is 18% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 69), near overbought. The nearest support is the Pivot S1 at $21.65, and the nearest resistance the swing high (Nov 16) at $21.86.
| RSI (14) | 69.33 | Strong, overbought above 70 | Neutral |
| MACD | 0.54 | Below its signal line | Bearish |
| Stochastic | 66.7 | Middle of its range | Neutral |
| ADX (14) | 32.5 | Trending up | |
| Williams %R | -19.8 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 141.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +3.6% | Change over 10 sessions | Bullish |
| ATR (14) | $0.43 | Typical daily range, 2.0% of price |
| RSI (14) | 76.52 | Overbought above 70 | Overbought |
| MACD | 1.16 | Above its signal line | Bullish |
| Stochastic | 91.4 | Near the top of its range | Overbought |
| ADX (14) | 25.6 | Trending up | |
| Williams %R | -6.2 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 164.8 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +19.2% | Change over 10 sessions | Bullish |
| ATR (14) | $0.90 | Typical daily range, 4.1% of price |
What happened before
See how TAK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TAK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options FlowPrices may be delayed
90DNo whale options trades in TAK in the last 90 days.
TAK Institutional Ownership
Full report →- ▲236 buying vs 130 selling
- ▲Shares held by funds +18.2%
- ▲Funds holding +19
- ▲Superinvestors: 4 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 400 | 381 | +5.0% |
| In funds' top 10 | 2 | 1 | +100.0% |
| Held by funds | – | – | – |
| New / increased | 60 / 176 | 61 / 147 | +13.5% |
| Reduced / sold out | 90 / 40 | 100 / 42 | −8.5% |
| Put/call ratio | 0.08 | 0.31 | −72.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
TAK Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4 | Giles Richard PlatfordPresident, IBU | Sale | 55,617 | $20.90 | $1.2M |
| Nov 2 | Teresa Marie BitettiPresident, OBU | Sale | 46,609 | $20.89 | $974K |
| Sep 14 | Lauren Rusckowski DupreyChief Transformation Officer | Sale | 34,535 | $18.54 | $640K |
| Sep 2 | Andrew Stewart PlumpPresident, R&D | Sale plan | 116,191 | $18.49 | $2.1M |
| Aug 19 | Andrew Stewart PlumpPresident, R&D | Sale plan | 19,651 | $18.49 | $363K |
| Aug 18 | Nicola Deidre Petal GreenwayChief Human Resources Officer | Sale | 12,980 | $18.11 | $235K |
From SEC Form 4 filings by TAK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TAK is in one of them and how their past TAK trades turned out.
TAK News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TAK in an article yet. Here's the latest on the wider market.
TAK Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Ro KhannaD · CA | Buy | $1K – $15K | Oct 9, 2026 | Nov 5, 2026 | 27 d |
| Virginia FoxxR · NC | Sell | $15K – $50K | Aug 29, 2023 | Sep 5, 2023 | 7 d |
| Dan GoldmanD · NY | Sell | $15K – $50K | Jul 10, 2023 | Aug 13, 2023 | 34 d |
| Dan GoldmanD · NY | Buy | $1K – $15K | Feb 27, 2023 | Mar 20, 2023 | 21 d |
| Virginia FoxxR · NC | Buy | $1K – $15K | Feb 16, 2023 | Mar 3, 2023 | 15 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Takeda Pharmaceutical Co
Takeda is a pharmaceutical company based in Tokyo, Japan, that makes and sells branded prescription medicines. Its products are sold in the United States, Europe, Japan and emerging markets such as China. Its customers include hospitals and medical institutions, insurers and managed care groups, pharmacy benefit managers, and government health programs. Its products face price pressure and competition from generic and biosimilar versions once patent or regulatory protection ends.
- Headquarters
- Tokyo, Japan









